“We are coming off a very important and successful few months for ProMIS as we reported positive top-line Phase 1a data and closed on a strong financing, which could bring in up to $122.7 million to support our Alzheimer’s candidate and pipeline compounds,” said Neil Warma, CEO of ProMIS Neurosciences.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PMN:
- ProMIS Neurosciences annouces data on pathogenic role of misfolded SOD1
- ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
- ProMIS Neurosciences presents preclinical data on ABO at AAIC
- ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
- ProMIS Neurosciences Advances in Alzheimer’s Treatment Trial
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue